Anti‐resorptive therapies with BPs or denosumab significantly reduced circulating angiogenic factors and vascularity in cancer patients (Girolami et al. 2016; Santini et al. 2003), but this was less effective than bevacizumab in terms of reducing circulating free VEGF (Loupakis et al. 2007). Here, VEGFA is linked to cancer.